Harmony Biosciences projects robust revenue growth for 2026, with preliminary net revenue of $868 million in 2025.
The company is on track to achieve blockbuster status in narcolepsy with WAKIX.
Harmony Biosciences is advancing its late-stage pipeline with promising formulations and ongoing clinical trials.
WAKIX Revenue Projection
2026 guidance suggests WAKIX net revenue of $1.0 - $1.04 billion, indicating strong growth potential.
Pitolisant Franchise Expansion
Strategic initiatives aim to extend the pitolisant franchise, introducing next-gen formulations for long-term value creation.
Robust Pipeline Development
The company's pipeline includes five ongoing Phase 3 registrational trials, targeting distinct CNS indications for future growth.
- Harmony Biosciences reported strong preliminary net product revenue for Q4 2025, showcasing consistent growth.
- The company's innovative strategies in narcolepsy treatment and pipeline advancements position it for sustained success in the biotech industry.
With a solid financial performance in 2025 and optimistic revenue guidance for 2026, Harmony Biosciences demonstrates resilience and innovation in the pharmaceutical sector, signaling potential for long-term growth and value creation.